Six thousand people. A new website. And the concept that changes the budget conversation.

This weeks newsletter is a little different.

Most weeks I have covered what is happening in the industry, what I have been thinking about, what has landed well and what has not. It is a dispatch from inside the work.

This week I want to step back and tell you something about the work itself. About where Unwritten Health is, how I got here, and what I have just changed.

Because something has shifted. And I think the people reading this deserve to hear about it directly.

When I started having conversations with clinical development teams, patient engagement/advocacy leads, medical affairs directors, and market access heads, I went in with a hypothesis. That the problem we were solving was a health equity problem. That the data gap around underserved communities in clinical research was fundamentally a justice issue that also happened to have commercial consequences.

Both of those things are true, I will never back away from that.

But the conversations over the last few months have taught me something I did not fully appreciate at the start.

The people I am talking to are not primarily looking for a justice argument. They are looking for a solution to a problem they cannot currently solve. And the problem is specific: they need patient experience data, in a form that holds up to regulatory and HTA scrutiny, across the underserved populations that EU JCA, MHRA, NICE, NHS DTAC, and NIHR now require them to evidence. And they need it at a point in the development timeline where it can still change something.

That is a procurement decision, not a values conversation. And the positioning we had was not meeting them at that decision point clearly enough.

So we rebuilt it.

The new Unwritten Health website is live. And I want to walk you through what is different and why.

The clearest thing we changed is the headline.

Unwritten Health helps pharma medical affairs and market-access teams, medical device and digital health developers, and NHS-facing evaluators put patient experience data into the submissions regulators, HTA bodies and payers now demand.

Submission-ready. That is the word that changed everything.

Not community engagement. Not diversity metrics. Not a nice-to-have for the patient strategy team. Evidence that goes into your JCA file, your NICE submission, your NHS DTAC application, your MHRA Inclusion and Diversity Plan. Formatted for the framework you are submitting to. Fixed scope. Fixed duration. Fixed price.

The Equity Engine still sits at the centre of everything we do. But we have sharpened how we describe what it produces, because the buyers we are talking to do not need a platform. They need an output that closes a specific regulatory gap, on a specific timeline, at a price they can put in a budget conversation.

That is what we now offer. And the website makes it clear.

One of the things I am most proud of on the new site is that we have named something that the industry has been circling for years without a clear term for it.

Inclusion debt.

Here is the definition.

Designing clinical development without lived-experience input creates a liability. Every protocol amendment driven by a feasibility failure, every screen-fail rate that reveals an eligibility criterion was drawn too tightly, every HTA query that asks why the clinical trial population does not reflect the people who will use the medicine, every DTAC deferral that flags an algorithm trained on unrepresentative data — these are repayments of inclusion debt.

The debt accrues silently during protocol design. It gets paid back loudly during recruitment, submission, and post-market surveillance. And it is always more expensive at the back end than it would have been at the front.

The numbers are not theoretical. For pharma, the Tufts Center for the Study of Drug Development puts unrealised prescription revenue from HTA delay at:

These are the numbers that belong in a budget conversation. Not the equity argument. The equity argument is right, and I will never stop making it. But the inclusion debt framing is what gets the procurement decision made.

The Regulatory Readiness Scorecard is live at unwritten.health/scorecard.

Twenty questions. Six domains: intended purpose, dataset representativeness, subgroup evidence, usability and access, post-market monitoring, and governance. You get a red, amber, green, or gold score, a plain-English diagnosis of which regulatory clauses you are exposed under, and the specific fixed-price engagement that closes each gap.

It takes fifteen minutes. It is free. And if you want a sales call afterwards, you ask for one. We do not assume.

Most of the people reading this newsletter work in organisations where the patient experience evidence question is live but not yet answered. They know the frameworks exist. They are not always sure where their current evidence file sits against what those frameworks require. The scorecard gives them a diagnosis before they have to make a procurement decision. And a diagnosis is a conversation starter, internally and with us.

We built it because the right starting point is not a sales call. It is an honest assessment of where you are. That is consistent with everything Unwritten Health is built on: the belief that if you put the right data in front of the right people at the right moment, decisions change.

I want to end on the number that matters most to me personally.

When I wrote to you a few months ago, the Equity Engine had 3,500 participants. As of this month, that number is 6,000.

Six thousand people, recruited through community partners, profiled on the eight social factors that shape health outcomes: age, ethnicity, first language, income, geography, disability, caring responsibilities, and health literacy. Six thousand people who chose to share their lived experience with us because someone they trusted in their community said this was different.

That trust is the only asset that cannot be bought, copied, or replicated on a faster timeline. It is what makes the data what it is. And it is what I feel the weight of every time we make a decision about how this company should operate, what it should say, and who it should serve.

The new website, the new positioning, the scorecard, the inclusion debt framework — all of it is built to make the commercial case for using this data properly. But the reason it exists is 6,000 people who decided, against a long history of reasons not to, that their experience was worth sharing.

That is what we are building. And it is nowhere near finished.

Thanks for reading. This newsletter exists because I believe the right framing, in the right hands, changes decisions. If it did that for you this week, even a little, that is enough.

Speak soon

Ashish